Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALXN2230 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Participants will be enrolled across multiple cohorts and will receive a single dose of placebo. |
| ALXN2230 | EXPERIMENTAL | Participants will be enrolled across multiple cohorts and will receive a single dose of ALXN2230. |
| Name | Type | Description |
|---|---|---|
| ALXN2230 | DRUG | Participants will receive ALXN2230 via SC injection. Optional cohort will receive ALXN2230 via SC infusion. |
| Placebo | DRUG | Participants will receive placebo via SC injection. Optional cohort will receive placebo via SC infusion. |
Inclusion Criteria: * Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring. * Baseline immunoglobulin G (IgG) concentrations ≥ 1000 milligrams per deciliter (mg/dL) and ≤ 1600 mg/dL at Scre...
ALXN2230 is an investigational small molecule drug being developed by AstraZeneca PLC. It is in Phase 1 clinical development, with a single trial currently recruiting. The specific disease or condition it is intended to treat has not been disclosed, and the study is being conducted in healthy adult participants rather than in patients with a named indication.
ALXN2230 is being developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is the sponsor of the Phase 1 study evaluating the compound. No partnership or licensing arrangement for ALXN2230 has been announced.
ALXN2230 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. One Phase 1 trial is currently recruiting, and no trials have been completed. The program remains in early-stage human testing.
ALXN2230 is being studied in one Phase 1 trial, NCT07352423, titled a Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN2230 in Healthy Participants. The trial is recruiting 48 healthy adult volunteers in the United Kingdom. It is randomized, double-blind, and placebo-controlled, and accepts participants aged 18 years and older of any sex.
The ALXN2230 Phase 1 trial, NCT07352423, is a randomized, double-blind, placebo-controlled study enrolling 48 healthy adult participants in the United Kingdom. It is currently recruiting and evaluates safety, tolerability, pharmacokinetics, and pharmacodynamics. Participants must be at least 18 years old, and both sexes are eligible. The study is not biomarker-selected.